Aandelen in “Productie van biologische producten”

Aandeel Datum Koers Evolutie
Even geduld...

Nieuws over “Productie van biologische producten”

18:00 · GENFIT Receives FDA Orphan Drug Designation for NTZ for the treatment of ACLF     · Persbericht

18:00 · GENFIT Receives FDA Orphan Drug Designation for NTZ for the treatment of ACLF     · Persbericht

6/03 · BetterInvesting™ Magazine Update on Equifax Inc. (NYSE: EFX) and Neurocrine Bio In. (NASDAQ: NBIX) · Persbericht

6/03 · RGNX SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds REGENXBIO Investors of Securities Class Action Deadline on April 14, 2026 · Persbericht

6/03 · U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma · Persbericht

5/03 · AMGEN TO PRESENT AT THE LEERINK PARTNERS 2026 GLOBAL HEALTHCARE CONFERENCE · Persbericht

5/03 · RGNX'S "TRANSFORMATIONAL" PROMISE BECAME A $2.40 LOSS FOR INVESTORS: SUEWALLST · Persbericht

5/03 · Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences · Persbericht

5/03 · REGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights · Persbericht

5/03 · Markten halen opnieuw adem · LYNX

Beursnieuws Amerika De Amerikaanse aandelenmarkten lijken de zorgen over de oorlog in Iran voorlopig even te vergeten. De Dow Jones en de S&P 500 stegen met 0,49% en 0,78% terwijl de technologie-index Nasdaq een winst...

4/03 · The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome · Persbericht

4/03 · Monthly information on share capital and company voting rights · Persbericht

4/03 · DBV Technologies to Participate in Upcoming March Investor Conferences · Persbericht

4/03 · AMGEN ANNOUNCES 2026 SECOND QUARTER DIVIDEND · Persbericht

4/03 · Wall Street: chipaandelen floreren op groene beurs · Tijd.be (€)

Beleggers laten de Iran-crisis links liggen en leggen techwaarden in hun koopmandje. Abercrombie stelt teleur met zijn prognose, terwijl Moderna fors opveert na een schikking.

4/03 · REGENXBIO Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - RGNX · Persbericht

4/03 · REGENXBIO Announces Presentations at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference · Persbericht

3/03 · Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of February 28, 2026 · Persbericht

3/03 · Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them · Persbericht

3/03 · Immunotherapy Delivers Across Tumor Types as Oncology Market Eyes $750 Billion · Persbericht

2/03 · REGENXBIO, Inc. Stockholders Have Rights - Stockholders Who Lost Money Investing in RGNX Should Contact Robbins LLP for Information About Recovering Their Losses · Persbericht

Mijn selecties